Carcinoid tumors are rare endocrine neoplasms arising from the enterochromaffin or enterochromaffin-like cells. Gastric carcinoids associated with autoimmune atrophic gastritis and hypergastrinemia, are usually multiple and the prognosis are better compared to solotary lesions with out hypergastrinemia. Gastric carcinoids are commonly associated with other endocrine disorders or tumors, but any associations with autoimmune disorders other than autoimmune atrophic gastritis have rarely been reported. Sjogren's syndrome is an autoimmune exocrinopathy that primarily affects the salivary glands, but it can also involve almost any other part of the gut. The most common form of gastrointestinal involvement in Sjogren's syndrome is chronic atrophic gastritis, which can lead to hypergastrinemia and the subsequent development of carcinoid. However, gastric carcinoid tumor associated with Sjogren's syndrome has not yet been reported on. To the best of our knowledge, this is the first such case in the world. We report on this case along with review of the related literature.
Carcinoid Tumor* ; Enterochromaffin-like Cells ; Gastritis, Atrophic ; Prognosis ; Salivary Glands ; Sjogren's Syndrome*

Proton-pump inhibitors (PPI) have important roles in the management of acid-related disorders, especially gastro-esophageal reflux disease and peptic ulcer disease. They are considered safe, but some side effects, such as oxyntic cell hyperplasia, glandular cysts, hypergastrinemia and fundic gland polyps, are also reported. Long-term PPI administration in Helicobacter pylori (H. pylori) positive subjects promotes a shift from antral to corpus-predominant gastritis. The shift leads to corpus atrophy eventually that is known predisposing factor of gastric adenocarcinoma. It is recommended that patients being considered for long-term PPI therapy should be tested for H. pylori infection. And if present, H. pylori eradication should be preceded to PPI administration. Also, long-term PPI administration can cause enterochromaffin-like cell hyperplasia. Although the underlying mechanism and pathogenesis are not yet fully understood, it is possible that long-term PPI administration can promote the development of gastric carcinoid tumor. Therefore, to minimize the side effects, it should be used in adequate dose for a precise duration.
Adenocarcinoma ; Atrophy ; Carbamates ; Carcinoid Tumor ; Enterochromaffin-like Cells ; Gastritis ; Gastritis, Atrophic ; Gastroesophageal Reflux ; Helicobacter pylori ; Humans ; Hyperplasia ; Organometallic Compounds ; Parietal Cells, Gastric ; Peptic Ulcer ; Polyps

Proton pump inhibitors (PPIs) are widely used over 20 years for management of symptoms due to acid related diseases such as peptic ulcer and reflux esophagitis. Serious adverse events are extremely rare for short-term PPIs use. Recently, as long-term PPIs use increase, diverse reports have been reported on adverse event related with long-term PPIs use. Long-term PPIs use is generally referred as use of PPIs more than 1 year. Secondary hypergastrinemia after long-term PPIs use is associated with development of fundic gland polyps (FGP) and hyperplasia of enterochromaffin-like cell (ECL) that might be concerned with gastric carcinoid tumor. Furthermore, several studies have posed the relationship between the risk of gastric cancer and long-term PPIs use with co-existing H. pylori infection. The present review summarize the recent accumulated evidence on neoplasm associated with secondary hypergastrinemia after long-term PPIs use.
Carcinoid Tumor ; Enterochromaffin-like Cells ; Esophagitis, Peptic ; Gastritis, Atrophic ; Hyperplasia ; Peptic Ulcer ; Polyps ; Proton Pump Inhibitors ; Proton Pumps ; Protons ; Stomach Neoplasms